Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

uch as glucagon-like peptide-1 (GLP-1) that help regulate blood glucose levels. In addition, LX4211 enhances excretion of glucose in the urine, which may also help to reduce the need for insulin, without causing low blood sugar or hypoglycemia. Lexicon expects to have results from an ongoing Phase 2b trial in type 2 diabetes by mid-year 2012.

About the Clinical Trial in Type 1 Diabetes
The initial Phase 2 proof-of-concept study will be a randomized, double-blinded, placebo-controlled trial in approximately 25 adult patients with type 1 diabetes who will receive LX4211 over a one month treatment period. The primary endpoint of the study will be reduction of insulin required with LX4211 as compared to placebo. Secondary endpoints will include multiple measures of blood sugar to show that LX4211 helps to maintain glycemic control during the treatment period. Under the agreement, additional funding could support future Phase 2 trials of LX4211 in type 1 diabetes.

About Type 1 Diabetes
An estimated 1.3 million people in the U.S. have type 1 diabetes, a chronic disease usually caused by autoimmune destruction of insulin-producing beta cells of the pancreas. The resulting decrease in insulin leads to high levels of glucose in the blood, which in turn can lead to acute metabolic complications as well as chronic problems with eyes, kidneys, nervous system and heart. If not properly controlled with insulin therapy, type 1 diabetes can be fatal. Patients with type 1 diabetes are at least 10 times more at risk for cardiovascular disease compared to people without diabetes. The rate of type 1 diabetes incidence among children under the age of 14 is estimated to increase by 3% annually worldwide.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irrita
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... -- Cardiva Medical, Inc. announced today that it has closed ... 3 private equity financing and a $12.5 million senior ... the proceeds of the Series 3 private equity financing ... VASCADE® Vascular Closure System in the United ... 3 private equity financing was a new investor, Canepa ...
(Date:8/19/2014)... Aug. 19, 2014  Sequence, Inc., an industry leader in ... and medical device manufacturers is opening a third office location ... , as a result of demand by clients to ... opened this month, allows Sequence to better serve new and ... St. Louis office provides Sequence a hub ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:8/19/2014)... (PRWEB) August 20, 2014 Midtown Dentistry in ... amalgam-free dental office. All patients with cavities, or with ... latest white fillings that can safely repair and restore teeth. ... the very latest materials, all of which are completely amalgam ... safe for use by the FDA for adults and children ...
(Date:8/19/2014)... What gives skin an edge and is that "something ... nourish it while lightly exfoliating? The Collagen Antioxidant ... about how their skin feels and looks after using the ... "The ingredients are very rich and spa-quality." , The special ... cleansed skin of the face and neck, and let it ...
(Date:8/19/2014)... editorial published in this week,s JAMA highlights ... tools when considering how to treat patients. Written by ... Center and chair of pediatrics at Boston University School ... JAMA , the editorial examines results of a study ... an example of how doctors can often over-emphasize certain ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 LunaDress, a ... and cocktail dresses for ladies, is now providing a ... prom dresses . The company’s cheap white prom outfits ... V-neck, backless, and A-line outfits. , There are ... company’s product category, and the special offer is valid ...
(Date:8/19/2014)... 2014 Top10BestSEOHosting.com has recently announced ... the recommended suppliers for the webmasters who want ... , According to the senior spokesman for Top10BestSEOHosting.com, ... affordable hosting products on the market and specializes ... variety of online deals when service plans are ...
Breaking Medicine News(10 mins):Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:That "Something Special" to Improve Skin Takes Only 10 Minutes Per Week; on Sale at Sublime Beauty® 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Fatcow Awarded As One of the Best Web Hosting Suppliers at Top10bestseohosting.com 2
... ... a leading provider of information-based technology services to the health care industry, ... Texas in addition to its services that are provided to physicians throughout ... New Hampshire and is owned by Medical Protective, part of the Berkshire ...
... NJ A recent study published in International ... extract from the bark of the French maritime pine ... associated with various health problems. Dr. Raffaella Canali ... in Rome, Italy, found that Pycnogenol inhibits the generation ...
... , , PORTLAND, Ore., ... reform is the power of simple questions that people can ask each ... , To spark this effort, Regence BlueCross ... to inspire debate, discussion, and ultimately engagement and action by consumers. As ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... HARRISBURG, Pa., July 15 The Department of Environmental Protection and ... day for June 16 in the Philadelphia region. , ... will be code ORANGE for ozone in the region, which includes ... , The U.S. Environmental Protection Agency,s standardized ...
... , PITTSBURGH, Jul. 15 Leo W. Gerard, President ... to the U.S. House of Representatives, health care reform bill. , ... ) , , ... of efforts by the U.S. House leadership to fix our broken ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:Study demonstrates the anti-inflammatory properties of pine bark extract 2Health News:Regence Launches Effort to Further Health Care Debate 2Health News:Regence Launches Effort to Further Health Care Debate 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Air Quality Action Day Forecast for July 16 in Philadelphia Region 2Health News:Statement by USW President Leo W. Gerard on U.S. House Health Care Reform Bill 2
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
... The Equalizer With 384 Well Plate Capability ... revolutionary features of the original Equalizerexpandable and equal ... components, and in-lab calibration capabilities. In addition, this ... down to 4.5mm for loading and accessing many ...
... Equally Spaced, Expandable, Multichannel Pipettor ... pipettors and instantly boosts productivity with an ... the simple adjustment of a slide rod. ... transfer of liquids between vessels with different ...
Medicine Products: